OncoGenex sinks, sees prostate potential after custirsen failure
This article was originally published in Scrip
OncoGenex Pharmaceuticals shares fell 60.3% after the company and its partner Teva Pharmaceutical Industries revealed that custirsen did not significantly improve survival versus chemotherapy for prostate cancer patients enrolled in the Phase III SYNERGY clinical trial.
You may also be interested in...
Custirsen, the lead drug candidate from OncoGenex, failed in a second Phase III clinical trial – a trial that may have represented the company's last, best hope of success.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.